Drug development risk in HIV-1 clinical trials: the effect of drug class

Published by: Brendan J.W. Osborne, Rupert Kaul and Jayson L. Parker

Brendan Osborne conducted this research as part of his training in the MBiotech Program. He is now conducting his Ph.D. in the Institute of Medical Science at the University of Toronto, on HIV infection.

Click here to view the journal article.